ClinicalTrials.gg
Not yet recruitingNCT07458620Neck LVAUpdated Mar 9, 2026

Prospective Single-Arm Safety Study of Cervical LVA in AD Patients

A Phase 1 interventional study of Supermicrosurgical Lymphaticovenular Anastomosis (LVA) in Alzheimer's Disease (AD), sponsored by Chang Gung Memorial Hospital. Not yet recruiting at 1 site in Taiwan. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-09.

Sponsored by Chang Gung Memorial Hospital · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital — 6 open to participants now, 6 under way, none of them phase 3. Alzheimer Disease · Chang Gung Memorial Hospital.

Planned enrollment
19th of 25
35 · median 67
Started
2026
with 1 other
Phase 1
3 of 27
1 open now
Registered
26th of 27
by date

Among the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, this one is the 19th largest by planned enrollment of the 25 interventional ones that give a count, is one of 2 that started in 2026, is one of 3 in phase 1, and was the 26th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

6 of the 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Alzheimer Disease by Chang Gung Memorial Hospital, or all of them as a file.
02

Study summary

Official Title Prospective Single-Arm Safety Study of Cervical Lymphaticovenular Anastomosis (LVA) in Patients with Alzheimer's Disease

Purpose of the Study Researchers are conducting this study to see if a minimally invasive microsurgery, called Cervical Lymphaticovenular Anastomosis (LVA), is safe for people with Alzheimer's Disease.

How the Surgery Works Alzheimer's Disease is linked to the buildup of metabolic waste products (certain proteins) in the brain. Recent medical discoveries show that these wastes normally drain through small channels in the neck into the blood system. In this study, surgeons will use high-powered microscopes to connect these drainage channels (lymphatic vessels) in the neck directly to small nearby veins. The goal is to create a "detour" that helps the brain clear out these harmful proteins more effectively.

What to Expect Safety First: The main goal is to find out if the surgery is safe and well-tolerated by patients.

The Procedure: The surgery is performed under general anesthesia and typically takes 4 to 6 hours. It involves small (about 5 cm) incisions on both sides of the neck.

Follow-up: Participants will be monitored for at least 12 months. Researchers will use memory tests, brain scans (MRI and PET), and blood tests to see if the surgery helps with daily activities or slows down memory loss.

Read the detailed description

Official Title Prospective Single-Arm Safety Study of Cervical Lymphaticovenular Anastomosis (LVA) in Patients with Alzheimer's Disease

Scientific Rationale Neurodegenerative diseases like Alzheimer's (AD) are characterized by the misfolding and accumulation of proteins such as Amyloid-beta and Tau. The glymphatic and meningeal lymphatic systems serve as the primary pathways for clearing these metabolic wastes from the central nervous system into the deep cervical lymph nodes. This study investigates whether enhancing this drainage via supermicrosurgical lymphaticovenular anastomosis (LVA) can reduce intracranial protein burden and systemic oxidative stress.

Study Design and Intervention This is a prospective, single-arm safety study. Participants undergo bilateral cervical LVA. Using Indocyanine Green (ICG) fluorescence lymphography for navigation, lymphatic vessels in the neck are identified and anastomosed to adjacent small veins to facilitate lymph drainage into the venous circulation.

Safety Monitoring and Data Integrity Primary Safety Endpoint: The study defines safety as a Serious Adverse Event (SAE) rate of ≤10% within the first month post-operation. Events are graded using CTCAE v5.0.

Independent Oversight: To ensure objectivity, cognitive and behavioral assessments (including MMSE, CDR, and CASI) are conducted by clinical psychologists who are not members of the core research team.

External Auditing: An independent Clinical Research Organization (CRO) has been contracted to perform four periodic audits to verify data accuracy and GCP compliance.

Exploratory Objectives

The study will track longitudinal changes in:

Fluid Biomarkers: Plasma levels of Amyloid-beta 40/42, p-Tau 217, GFAP, and Nf-L at baseline, 1, 6, and 12 months.

Neuroimaging: Amyloid-PET and FDG-PET scans at baseline and 12 months to evaluate protein deposition and metabolic activity.

Clinical Outcomes: Changes in cognitive scores (CDR, MMSE, CASI, NPI) from baseline to 6 months post-surgery.

03

Conditions studied

  • Alzheimer's Disease (AD)

Keywords

  • Alzheimer's Disease (AD)
  • Neurodegenerative Diseases
  • Dementia
  • Lymphaticovenular Anastomosis (LVA)
  • Supermicrosurgery
  • Cervical Lymphatic Bypass
  • Glymphatic System Clearance
  • Meningeal Lymphatic System
  • Amyloid-beta (Aβ) Drainage
  • Tau Protein Clearance
  • CSF
  • Deep Cervical Lymph Nodes (dCLNs)
  • Amyloid-PET Imaging
  • Indocyanine Green (ICG) Lymphography
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Diagnosis of Alzheimer's Disease: Participants must have a confirmed diagnosis of Alzheimer's Disease as evaluated by a neurologist and a psychiatrist at the hospital.
  • Positive Amyloid-PET Scan: The result of a [18F] Florbetapir (Amyloid-PET) scan must be positive, indicating the presence of amyloid plaques in the brain.
  • Willingness to Consent: Participants or their legal representatives must be willing to sign a written form.
  • Participants must be adults aged 18 years or older

Exclusion criteria

Exclusion Criteria:

  • Lack of : Potential participants are excluded if they are unable to exercise autonomy and informed consent cannot be obtained from a legal representative or authorized person.
  • Prior Surgical History: Individuals who have previously undergone neck lymphatic dissection, nasopharyngeal surgery, or intracranial surgery are excluded.
  • Concurrent Medical Conditions: The trial excludes persons with thyroid disease or chronic heart failure.
  • Specific Allergies: Candidates with a history of allergies to shellfish or iodine are excluded due to the use of Indocyanine Green (ICG) during the procedure.
  • Unresolved Concerns: Anyone who has doubts about the trial and cannot receive satisfactory answers is excluded.
  • Anesthesia Risks: Individuals deemed medically unfit for general anesthesia-for example, those with severe cardiopulmonary insufficiency or a history of specific anesthetic drug allergies-are ineligible.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (estimated)

Study arms

  • Experimental
    Single-Arm Cervical LVA Intervention Supporting Context Arm Type

    The single experimental arm involves bilateral cervical supermicrosurgical Lymphaticovenular Anastomosis (LVA). Participants undergo a surgical procedure where high-power microscopy is used to identify cervical lymphatic vessels. These vessels are then microsurgically connected (anastomosed) to adjacent small veins to create an extra-cranial bypass. The intervention utilizes Indocyanine Green (ICG) fluorescence imaging to precisely map the lymphatic drainage pathways in the neck. The primary goal of this bypass is to enhance the clearance of metabolic waste-specifically Amyloid-beta and tau proteins-from the brain by facilitating their drainage from the glymphatic and meningeal lymphatic systems into the systemic venous circulation. This trial evaluates the safety and feasibility of this approach in mitigating the progression of Alzheimer's Disease.

    Procedure: Supermicrosurgical Lymphaticovenular Anastomosis (LVA)

Interventions

  • ProcedureSupermicrosurgical Lymphaticovenular Anastomosis (LVA)

    This intervention is uniquely distinguished by its use of supermicrosurgery to perform bilateral cervical Lymphaticovenular Anastomosis (LVA) as a direct physiological treatment for Alzheimer's Disease. Unlike traditional pharmacological trials that target protein production or aggregation, this surgical approach focuses on the mechanical clearance of metabolic waste. A key technical differentiator is the specific targeting of neck lymph nodes using Indocyanine Green (ICG) fluorescence to map the drainage pathway of cerebrospinal fluid. This allows for a precise, "super-microsurgical" bypass (connecting vessels often \<0.8mm) in the neck. This method aims to bypass potential blockages in the aging dCLNs (deep cervical lymph nodes), directly enhancing the outflow of Amyloid-beta and Taufrom the glymphatic and meningeal systems into the venous circulation.

06

What researchers measure

Primary outcomes

  1. Incidence of Treatment-Emergent Adverse Events (Safety and Feasibility)

    Assessment of the safety and feasibility of bilateral cervical supermicrosurgical lymphaticovenular anastomosis (LVA). Safety is evaluated by the frequency and severity of adverse events (AEs) and serious adverse events (SAEs) occurring from the start of the surgical procedure through the 1-month post-operative follow-up period. Events are graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 5.0.

    Time frame: From the start of surgery up to 1 month post-operation.

Secondary outcomes

  1. Change from Baseline in Mini-Mental State Examination (MMSE) Score

    A 30-point questionnaire used to measure cognitive impairment. Lower scores indicate greater impairment.

    Time frame: Baseline and 6 months post-operation

  2. Change from Baseline in Clinical Dementia Rating (CDR)

    A scale used to characterize the level of cognitive and functional performance.

    Time frame: Baseline and 6 months post-operation.

  3. Changes from Baseline in Cognitive Abilities Screening Instrument (CASI)

    The CASI is a comprehensive tool used to assess multiple cognitive domains, including attention, concentration, orientation, short-term memory, long-term memory, language abilities, visual construction, list-generating fluency, and abstraction. It provides a more detailed assessment than the MMSE, with a total score ranging from 0 to 100. Higher scores indicate better cognitive performance, while lower scores represent greater impairment.

    Time frame: Baseline and 6 months post-operation.

  4. Change in Brain Amyloid-beta Deposition via PET Scan

    Assessment of the change in brain amyloid plaque density using \[18F\] Florbetapir (Amyloid-PET) imaging. This measures whether the surgical intervention has facilitated the clearance of pathological proteins.

    Time frame: Baseline and post-operation.

  5. Change in Plasma Neurodegenerative Biomarker Levels

    Quantification of plasma levels for GFAP and NfL. These markers are used to track neuroaxonal damage and protein clearance efficiency.

    Time frame: Baseline and post-operation.

07

Study locations

1 site
08

References and documents

Publications

  • Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J. Structural and functional features of central nervous system lymphatic vessels. Nature. 2015 Jul 16;523(7560):337-41. doi: 10.1038/nature14432. Epub 2015 Jun 1. PubMed 26030524 ↗
  • Hong JP, Chen WF, Nguyen DH, Xie Q. A Proposed Role for Lymphatic Supermicrosurgery in the Management of Alzheimer's Disease: A Primer for Reconstructive Microsurgeons. Arch Plast Surg. 2025 Jan 30;52(2):96-103. doi: 10.1055/a-2513-4313. eCollection 2025 Mar. PubMed 40083619 ↗

Individual participant data

Plan to share: No — Data Protection and Retention Limits: The protocol strictly mandates that all de-identified data and specimens will be destroyed five years after the formal conclusion of the trial. Privacy and Confidentiality: To protect the privacy of participants, data is stored under locked and encrypted conditions, with access restricted to the immediate research team members. Restricted Future Use: While participants can consent to have their data stored in the hospital's internal biobank, this authorization is limited specifically to future research within Kaohsiung Chang Gung Memorial Hospital and does not extend to public or external sharing. Legal Representative Consent: Because the study involves participants with cognitive impairments who may lack the capacity to exercise autonomy, data management is subject to strict ethical oversight that prioritizes the protection of the participants' rights over broad data dissemination.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for May 2027, 14 months later.

Of 73 non-industry phase 1 interventional studies under Alzheimer Disease, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 57. This study's planned 14 months is below that.

Counting every sponsor, half of 236 studies reached it within 17 months; a quarter within 7 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2026
First posted
Mar 9, 2026
StartEst.
Mar 2026
Primary completionEst.
May 2027
CompletionEst.
Sep 2028
Last update
Mar 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07458620
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Mar 2026 (estimated)
Primary completion
May 2027 (estimated)
Completion
Sep 2028 (estimated)
Last update
Mar 9, 2026

Study contacts

Johnson Chia-Shen Yang,, MD, PhD
Contact
johnson.c.yang@gmail.com
+886-975056253

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion